Supplementary Figure 3 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Hojabr Kakavand; James S. Wilmott; Alexander M. Menzies; Ricardo E. Vilain; Lauren E. Haydu; Jennifer H. Yearley; John F. Thompson; Richard F. Kefford; Peter Hersey; Georgina V. Long; Richard A Scolyer

doi:10.1158/1078-0432.22458542

Preprint2023

Supplementary Figure 3 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A Scolyer

Preprint2023

Supplementary Figure 2 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A Scolyer

Preprint2023

Supplementary Figure 2 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A Scolyer

Preprint2023

Supplementary Figure 1 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A Scolyer

Preprint2023

Supplementary Figure 4 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A Scolyer

Supplementary Figure 3 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Abstract

Discussion(0)

Open reviews(0)

Related publications

Supplementary Figure 3 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Supplementary Figure 2 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Supplementary Figure 2 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Supplementary Figure 1 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Supplementary Figure 4 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients